U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C22H27N3O3S
Molecular Weight 413.533
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ETHACIZINE

SMILES

CCOC(=O)NC1=CC=C2SC3=CC=CC=C3N(C(=O)CCN(CC)CC)C2=C1

InChI

InChIKey=PQXGNJKJMFUPPM-UHFFFAOYSA-N
InChI=1S/C22H27N3O3S/c1-4-24(5-2)14-13-21(26)25-17-9-7-8-10-19(17)29-20-12-11-16(15-18(20)25)23-22(27)28-6-3/h7-12,15H,4-6,13-14H2,1-3H3,(H,23,27)

HIDE SMILES / InChI

Molecular Formula C22H27N3O3S
Molecular Weight 413.533
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ethacizine (ethacyzine) is a class Ic antiarrhythmic agent, related to moracizine. It is used in Russia and some other Commonwealth of Independent States countries for the treatment of severe and/or refractory ventricular and supraventricular arrhythmias, especially those accompanied by organic heart disease. It is also indicated as a treatment of refractory tachycardia associated with Wolff–Parkinson–White syndrome.

Originator

Sources: Farmakologiya i Toksikologiya (Moscow) (1971), 34, (2), 163-7.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Ethacyzin

Approved Use

Unknown
Primary
Ethacyzin

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
63.7 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHACIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
571.6 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHACIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.7 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
ETHACIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
PubMed

PubMed

TitleDatePubMed
[Atrial fibrillation: choice of the method of pharmacological cardioversion].
2005
Ethacizin metabolism in humans.
1989-07
Patents

Patents

Sample Use Guides

In Vivo Use Guide
The initial dose is 50 mg (1 table) 2-3 times a day. In case of insufficient clinical effect, the dose is increased (under compulsory ECG monitoring) to 50 mg 4 times a day (200 mg) or 100 mg 3 times daily (300 mg).
Route of Administration: Oral
In Vitro Use Guide
Ethacizine applied in the concentration range between 1 X 10(-7) and 1 X 10(-5) g/ml decreased the rate of action potential growth (Vmax) of the mammal myocardium. Inhibition of the Vmax was accompanied by the diminution of the force of contraction which involved two phases. Ethacizine also decreased the overshoot of slow response action potential with the time constant similar to that in the first rapid phase of force reduction.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:15:10 GMT 2025
Edited
by admin
on Mon Mar 31 19:15:10 GMT 2025
Record UNII
FE5SPV1Z6G
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ETMOZINE DAA
Preferred Name English
ETHACIZINE
MART.   WHO-DD  
Common Name English
ETHACIZIN
Common Name English
ETHACIZINE [MART.]
Common Name English
NSC-621878
Code English
ETHACYZIN
Common Name English
Ethacizine [WHO-DD]
Common Name English
EZ-55
Code English
ETHYL 10-(3-(DIETHYLAMINO)PROPIONYL)PHENOTHIAZINE-2-CARBAMATE
Common Name English
ETACIZIN
Common Name English
NIK-244
Code English
Classification Tree Code System Code
WHO-VATC QC01BC09
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
WHO-ATC C01BC09
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
Code System Code Type Description
NSC
621878
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
PUBCHEM
107841
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
DRUG CENTRAL
4835
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
SMS_ID
100000126035
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
CAS
33414-33-4
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
FDA UNII
FE5SPV1Z6G
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
WIKIPEDIA
Ethacizine
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
EVMPD
SUB32872
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
MESH
C046818
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
EPA CompTox
DTXSID50187057
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
ChEMBL
CHEMBL1997663
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
DRUG BANK
DB13645
Created by admin on Mon Mar 31 19:15:10 GMT 2025 , Edited by admin on Mon Mar 31 19:15:10 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT